Table 2.
Summary of the clinical characteristics of the sample (N = 25)
| Variable | Statistic |
|---|---|
| Renal replacement therapy (n, %) | |
| In pre‐dialysis care | 5 (20) |
| Hospital‐based HD | 7 (28) |
| Home‐based HD | 3 (12) |
| CAPD | 2 (8) |
| APD | 3 (12) |
| Transplant recipient (Tx) | 5 (20) |
| Transplant status (n, %) | |
| Active | 2 (8) |
| Working up | 7 (28) |
| Unfit reconsider/Unfit permanent | 9 (36) |
| Off by patient request | 2 (8) |
| N/A – currently transplanted | 5 (20) |
| Previous episodes of graft rejection (n, %) | |
| Yes | 5 (20) |
| No | 20 (80) |
| Time since CKD diagnosis in yrs (mean, SD, range, n) | 8.70 (7.23, 1.24–35.49, 20) |
| Time since progression to ESKD in yrs (mean, SD, range, n) | 5.64 (6.41, 0.11–26.49, 25) |
| Primary renal diagnosis (n, %)a | |
| Renal vascular disease due to hypertension | 10 (40) |
| Type 2 diabetes | 7 (28) |
| Glomerulonephritis | 4 (16) |
| Polycystic kidney disease | 2 (8) |
| Congenital absence of second kidney | 2 (8) |
| Other | 4 (16) |
| Renal function eGFR (mean, SD, range) | 17.64 (17.27, 4–67) |
| Comorbidities (n, %) | |
| Yes | 23 (92) |
| No | 2 (8) |
| Dialysis vintage (yrs) (mean, SD, range) | 2.70 (2.99, 0.24–12.46) |
| Time since Tx (yrs) (mean, SD, range) | 5.28 (4.39, 0.46–9.42) |
| HD adequacy via URR (%) (mean, SD, range) | 67.20 (7.67, 58–83) |
| IDWL (kg) (mean, SD, range, n) | −1.45 (0.90, −3.0 to −0.5, 10) |
| BMI (mean, SD, range, n) | 28.53 (6.83, 18.6–49.8) |
| Blood pressure (mean, SD, range, n) | |
| Systolic | 132.24 (22.70, 90–171) |
| Diastolic | 74.12 (15.13, 47–98) |
| Number of medications prescribed (mean, SD, range, n) | 9.36 (3.55, 2–16) |
| Receipt of ESA (n, %) | |
| Yes | 14 (56) |
| No | 11 (44) |
n = total number; SD = standard deviation; HD = haemodialysis; CAPD = continuous ambulatory peritoneal dialysis; APD = automated peritoneal dialysis; Tx = transplant; yrs = years; eGFR = glomerular filtration rate; URR = urea reduction ratio; IDWL = intra‐dialytic weight loss, BMI = body mass index; ESA = erythropoiesis‐stimulating agent.
a
Exceeding 100% because some participants reported multiple precursors of CKD.